We will publish a full set of global data and results in 2018.

On our results pages here, we have presented a selection of findings from our previous UK-focused study of infectious disease research investments.

Taken from the summary paper published in Lancet Infectious Diseases, 2013

We identified 6165 infectious disease studies with a total investment of £2·6 billion. Studies with a clear global health component represented 35·6% of all funding (£927 million).

By disease, HIV received £461 million (17·7%), malaria £346 million (13·3%), tuberculosis £149 million (5·7%), influenza £80 million (3·1%), and hepatitis C £60 million (2·3%). We compared funding with disease burden (DALYs and mortality) to show low levels of investment relative to burden for gastrointestinal infections (£254 million, 9·7%), some neglected tropical diseases (£184 million, 7·1%), and antimicrobial resistance (£96 million, 3·7%). Virology was the highest funded category (£1 billion, 38·4%). Leading funding sources were the Wellcome Trust (£688 million, 26·4%) and the Medical Research Council (£673 million, 25·8%).


See the video of Michael Head lecturing on this subject at the Royal Society of Medicine (November 2012).

Also see the video from a meeting run by the British Society for Antimicrobial Chemotherapy (February 2015), and listen to the presentation from the Cambridge-led Symposium for Biological and Life Sciences Students.

Tweet about this on TwitterShare on Google+Share on LinkedInShare on Facebook